Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

HDFC Life - Q1 FY22 Result Report - YES Securities

Posted On: 2021-07-22 06:31:34 (Time Zone: UTC)

(Rating: ADD, TP: Rs769, Upside: 12%)

Our view: HDFC Life performance in Q1 FY22 was broadly in line with estimates. Reserving of Rs7bn for COVID claims seems adequate currently. However, a third wave of COVID can be detrimental. Company has calibrated its approach towards protection business considering the risks associated with. The focus is on non par and annuity products. For the remainder of the year we are working with a 13% APE growth and 16% VNB growth, which is fairly achievable. During FY21-24E we expect APE CAGR of 14.4% and VNB CAGR of 17.8%. Based on discounted VNB approach to valuation we arrive at a fair value of Rs769. Retain ADD rating.

- APE - APE at Rs 15.6bn was lower than our estimate of Rs16.7bn. APE growth was at 30.1% yoy. Growth was driven by strong performance across all product classes except protection which was flat.

- APE Mix - Share of Non-Par business jumped 574bps. This was offset by decline of 111bps, 83bps and 179bps decline in share of ULIPs, Par and Individual Protection respectively.

- VNB & VNB Margin - Q1 FY22 VNB at Rs4.1bn was lower than our forecasts of Rs4.4bn, while VNB margin at 26.3% was in line with our estimates. On a yoy basis VNB margins improved by 202bps and sequentially margins declined by 70bps.

- EV - EV stands at Rs273bn, a growth of 21% on yoy basis.

Shares of HDFC Life Insurance Company Ltd was last trading in BSE at Rs. 663.6 as compared to the previous close of Rs. 678.6. The total number of shares traded during the day was 130323 in over 6425 trades.

The stock hit an intraday high of Rs. 681.7 and intraday low of 662. The net turnover during the day was Rs. 87510953.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Godrej Properties - Positives priced in - HDFC Securities

Maintain ADD on Dabur - Outperformance continues; strategies playing out - HDFC Securities

Orient Cement - On a strong footing - HDFC Securities

Kajaria Ceramics - Cost controls cushion margin hit - HDFC Securities

Maintain REDUCE on Emami - Sustaining expectation; margin base to impact FY22 - HDFC Securities

Bharti Airtel - Earnings Update - Inline - YES Securities

Tata Consumer - Q1 FY22 result first cut - YES Securities

Dabur India Ltd - Q1 FY22 Result Report - YES Securities

Castrol India Ltd - Q2 CY21 Result Report - YES Securities

Sunteck Realty Ltd - Q1 FY22 Result Report - YES Securities

Top brokerage houses have given 'subscribe' rating for Windlas Biotech Ltd IPO

Maintain BUY on Cholamandalam Investment and Finance Company - HDFC Securities

Maintain REDUCE on Britannia Industries - Beat on revenue; in-line EBITDA - HDFC Securities

Aditya Birla Fashion and Retail - Recovery better than expected - HDFC Securities

Vinati Organics Limited - High input costs dent margins - HDFC Securities

Q1FY22 Result Update - Colgate-Palmolive (India) - ICICI Direct

Q1FY22 Result Update - Tech Mahindra - ICICI Direct

Q1FY22 Result Update - Gateway Distriparks - ICICI Direct

Q1FY22 Result Update - Filatex India - ICICI Direct

Q1FY22 Result Update - KPR Mill - ICICI Direct

Q1FY22 Company Update - Mahindra Lifespace Developers - ICICI Direct

Maintain ADD on V-Guard Industries - Loss of peak season sales, state mix impact the show - HDFC Securities

Maintain REDUCE on RBL Bank - The pitfalls of 'banking' on a single engine - HDFC Securities

Maintain BUY on NTPC - Asset monetisation on the cards - HDFC Securities

Krsnaa Diagnostics Ltd. - IPO - Heathy Business Outlook with Sound OCF - Reliance Research

KEC International - Muted performance - HDFC Securities

Maintain BUY on Kansai Nerolac - GM pressure palpable - HDFC Securities

Auto Sector - July 2021 Sales - Acuité Ratings & Research

Indian Oil Corporation - Muted performance - HDFC Securities

Cholamandalam Investment & Finance - Q1 FY22 Result Report - YES Securities

HDFC Limited - Q1 FY22 Result Report - YES Securities

RBL Bank - Q1FY22 Result Update - YES Securities

Oberoi Realty Ltd - Q1 FY22 Result Report - YES Securities

Emami Ltd - Q1 FY22 Result Report - YES Securities

Britannia Industries - Q1 FY22 Result Report - YES Securities

Indian Oil Corp. Ltd - Q1FY22 Result Report - YES Securities

Container Corporation - Good results; ICD Khatuwas now connected to DFC - HDFC Securities

Maintain ADD on Marico - Food remains a showstopper; expect margin recovery - HDFC Securities

Maintain REDUCE on LIC Housing Finance - It's all going pear-shaped - HDFC Securities

JSW Energy - Adj PAT in line, but valuation remains stretched - HDFC Securities

JK Lakshmi Cement - Q1 hit by lower sales and fuel inflation; outlook bright - HDFC Securities

Upgrade to BUY on Sun Pharma - Strong beat, encouraging trends in specialty - HDFC Securities

Maintain ADD on Shriram Transport Finance Company - Cumulative stress on par with bellwether peer - HDFC Securities

EXIDE 1QFY22 - first cut - Weak margins drag PAT - Not rated - YES Securities

IOCL - 1QFY22 earnings update - YES Securities

Dr Lal PathLabs - Q1 FY22 first cut - Beat across the board - YES Securities

Chola Q1 FY22 first take - Strong PPOP show, but dejects on asset quality - YES Securities

Britannia - Q1 FY22 results first cut - YES Securities

Shriram City Union Finance Ltd - Q1 FY22 Call Highlights (Not Rated) - YES Securities

Sun Pharma - Q1 FY22 Result Report - YES Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020